8legs: Vyome holdings, inc.

#1 out of 1

Vyome Holdings, Inc Announces Key Findings on VT-1953

Vyome reports VT-1953 valued at $455 million after Phase 2, with potential to hit $1 billion post-Phase 3.
Estimated peak U.S. sales for VT-1953 are about $600 million annually.
The U.S. MFW treatment market is about $2.2 billion in total addressable market.
Vyome aims for VT-1953 to be the first FDA-approved therapy for MFW symptoms.
Destum Partners conducted the independent market analysis for Vyome.
The summary notes the information is AI-generated and may contain inaccuracies.
The filing cited is Vyome's 8-K dated January 28, 2026.
The report stresses the information is based on SEC documents and should be verified.
The release positions VT-1953 within a broader $2.2 billion MFW market in the U.S.

Vote 0